UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 213

Sortiert nach

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.522-528

2010

Volltextzugriff (PDF)

SP0164 Comorbidity of RA and Other Rheumatic Diseases

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.40-40

Hyrich, K.

2015

Volltextzugriff (PDF)

Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register

Rheumatology (Oxford, England), 2006-12, Vol.45 (12), p.1558-1565

2006

Volltextzugriff (PDF)

Assessing the safety of new drugs during pregnancy

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.18-19

Hyrich, K.L.

2018

Volltextzugriff (PDF)

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2011-10, Vol.70 (10), p.1810-1814

2011

Volltextzugriff (PDF)

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2010-06, Vol.69 (6), p.1086-1091

2010

Volltextzugriff (PDF)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.209-215

2009

Volltextzugriff (PDF)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.318-327

2023

Volltextzugriff (PDF)

Biologic therapies and pregnancy: the story so far

Rheumatology (Oxford, England), 2014-08, Vol.53 (8), p.1377-1385

2014

Volltextzugriff (PDF)

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

Annals of the rheumatic diseases, 2004-12, Vol.63 (12), p.1538-1543

2004

Volltextzugriff (PDF)

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

Rheumatology (Oxford, England), 2010-11, Vol.49 (11), p.2217-2219

2010

Volltextzugriff (PDF)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

Annals of the rheumatic diseases, 2009-01, Vol.68 (1), p.69-74

2009

Volltextzugriff (PDF)

Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey

British journal of dermatology (1951), 2021-07, Vol.185 (1), p.80-90

2021

Volltextzugriff (PDF)

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

Arthritis care & research (2010), 2010-06, Vol.62 (6), p.755-763

2010

Volltextzugriff (PDF)

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug

Rheumatology (Oxford, England), 2008-07, Vol.47 (7), p.1000-1005

2008

Volltextzugriff (PDF)

Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification

American journal of epidemiology, 2009-04, Vol.169 (7), p.909-917

2009

Volltextzugriff (PDF)

THU0627 Differences in DAS28-CRP and DAS28-ESR Influence Disease Activity Stratification in Rheumatoid Arthritis and Could Influence Use of Biologics, Treatment Efficacy Evaluations and Decisions Regarding Treat-To-Target: An Analysis Using The BSRBR-RA

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.420

2016

Volltextzugriff (PDF)

The British Society for Rheumatology Biologics Register: 6 years on

Rheumatology (Oxford, England), 2008-10, Vol.47 (10), p.1441-1443

2008

Volltextzugriff (PDF)

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

Annals of the rheumatic diseases, 2006-07, Vol.65 (7), p.895-898

2006

Volltextzugriff (PDF)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

Rheumatology (Oxford, England), 2010-04, Vol.49 (4), p.697-705

2010

Volltextzugriff (PDF)

SAT0095 Control of Disease Activity is Associated with Improvement in Physical Activity in Patients with Rheumatoid Arthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.624

2014

Volltextzugriff (PDF)

AB0005 Weighted Gene Co-Expression Network Analysis Reveals Link between Protein Kinase Signalling and Response To Methotrexate in New-Onset Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.898-898

2016

Volltextzugriff (PDF)

OP0174 The Development of The Modified DAS28-CRP To Improve Agreement with DAS28-ESR and Ensure Appropriate Disease Activity Stratification in RA

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.121-122

2016

Volltextzugriff (PDF)

THU0614 Forewarned Is Forearmed? Risk Communication during The Commencement of Methotrexate; Presenting The Clinicians' & Patients' Perspectives

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.414-415

2016

Volltextzugriff (PDF)

Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study

Rheumatology (Oxford, England), 2008-07, Vol.47 (7), p.991-995

2008

Volltextzugriff (PDF)

1 – 25 von 213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(204)
Mit Volltextzugriff
(191)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(93)
Life Sciences & Biomedicine
(92)
Humans
(88)
Rheumatology
(87)
Arthritis, Rheumatoid - Drug Therapy
(60)
Rheumatoid Arthritis
(58)
Female
(54)
Male
(52)
Antirheumatic Agents - Therapeutic Use
(50)
Middle Aged
(49)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(45)
Biological And Medical Sciences
(38)
Medical Sciences
(38)
Aged
(37)
Diseases Of The Osteoarticular System
(36)
Adult
(32)
Inflammatory Joint Diseases
(32)
Antirheumatic Agents - Adverse Effects
(26)
Registries
(26)
Tumor Necrosis Factor-Tnf
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

SP0164 Comorbidity of RA and Other Rheumatic Diseases

Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register

Assessing the safety of new drugs during pregnancy

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis

Biologic therapies and pregnancy: the story so far

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug

Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification

THU0627 Differences in DAS28-CRP and DAS28-ESR Influence Disease Activity Stratification in Rheumatoid Arthritis and Could Influence Use of Biologics, Treatment Efficacy Evaluations and Decisions Regarding Treat-To-Target: An Analysis Using The BSRBR-RA

The British Society for Rheumatology Biologics Register: 6 years on

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

SAT0095 Control of Disease Activity is Associated with Improvement in Physical Activity in Patients with Rheumatoid Arthritis

AB0005 Weighted Gene Co-Expression Network Analysis Reveals Link between Protein Kinase Signalling and Response To Methotrexate in New-Onset Rheumatoid Arthritis

OP0174 The Development of The Modified DAS28-CRP To Improve Agreement with DAS28-ESR and Ensure Appropriate Disease Activity Stratification in RA

THU0614 Forewarned Is Forearmed? Risk Communication during The Commencement of Methotrexate; Presenting The Clinicians' & Patients' Perspectives

Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study

Suchergebnisse filtern